NurExone Biologic Statistics
Total Valuation
NRXBF has a market cap or net worth of 42.07 million. The enterprise value is 41.14 million.
| Market Cap | 42.07M |
| Enterprise Value | 41.14M |
Important Dates
The next estimated earnings date is Monday, March 30, 2026.
| Earnings Date | Mar 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 90.75M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +27.20% |
| Shares Change (QoQ) | +2.05% |
| Owned by Insiders (%) | 5.15% |
| Owned by Institutions (%) | n/a |
| Float | 86.08M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 28.88 |
| P/TBV Ratio | 28.88 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -6.30 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -7.97 |
Financial Position
The company has a current ratio of 1.33, with a Debt / Equity ratio of 0.05.
| Current Ratio | 1.33 |
| Quick Ratio | 1.28 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.02 |
| Interest Coverage | -109.69 |
Financial Efficiency
Return on equity (ROE) is -298.06% and return on invested capital (ROIC) is -179.98%.
| Return on Equity (ROE) | -298.06% |
| Return on Assets (ROA) | -129.23% |
| Return on Invested Capital (ROIC) | -179.98% |
| Return on Capital Employed (ROCE) | -362.78% |
| Weighted Average Cost of Capital (WACC) | 5.60% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +8.23% in the last 52 weeks. The beta is 0.23, so NRXBF's price volatility has been lower than the market average.
| Beta (5Y) | 0.23 |
| 52-Week Price Change | +8.23% |
| 50-Day Moving Average | 0.51 |
| 200-Day Moving Average | 0.52 |
| Relative Strength Index (RSI) | 42.57 |
| Average Volume (20 Days) | 3,964 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -6.47M |
| Pretax Income | -6.54M |
| Net Income | -6.54M |
| EBITDA | -6.33M |
| EBIT | -6.47M |
| Earnings Per Share (EPS) | -0.09 |
Balance Sheet
The company has 983,000 in cash and 79,000 in debt, with a net cash position of 904,000.
| Cash & Cash Equivalents | 983,000 |
| Total Debt | 79,000 |
| Net Cash | 904,000 |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 1.46M |
| Book Value Per Share | 0.02 |
| Working Capital | 284,000 |
Cash Flow
In the last 12 months, operating cash flow was -5.07 million and capital expenditures -92,000, giving a free cash flow of -5.16 million.
| Operating Cash Flow | -5.07M |
| Capital Expenditures | -92,000 |
| Free Cash Flow | -5.16M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NRXBF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -27.20% |
| Shareholder Yield | -27.20% |
| Earnings Yield | -15.53% |
| FCF Yield | -12.27% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |